About: http://data.cimple.eu/news-article/4c3d667bbde0614247cadcb095f7e134a24ffb7b66444333848f5db3

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/4c3d667bbde0614247cadcb095f7e134a24ffb7b66444333848f5db3 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pharma giants Sanofi and GSK said Wednesday they have agreed to supply Britain with up to 60 million doses of a potential COVID-19 vaccine. The agreement covers a vaccine candidate developed by France's Sanofi in partnership with the UK's GSK and is subject to a "final contract". Amid a global race to find a vaccine to halt the pandemic, Sanofi announced "ongoing discussions with the European Commission, with France and Italy on the negotiation team, and other governments to ensure global access to a novel coronavirus vaccine." Both companies voiced in a statement their commitment "to making their COVID-19 vaccine candidate affordable and available globally". The vaccine candidate "has the potential to play a significant role in overcoming the COVID-19 pandemic, both in the UK and around the world," said GSK Vaccines President Roger Connor. Sanofi predicted regulatory approval for the vaccine "could be achieved by the first half of 2021". UK Business Secretary Alok Sharma, quoted in the statement, hailed the progress but noted "the fact remains that there are no guarantees". "In the meantime, it is important that we secure early access to a diverse range of promising vaccine candidates, like GSK and Sanofi, to increase our chances of finding one that works so we can protect the public and save lives." Britain has already secured access to 90 million doses of potential coronavirus vaccines in deals with biotech firms BioNTech, Pfizer and Valneva. The deals involve 30 million doses of a vaccine being developed by US pharma giant Pfizer and Germany's BioNTech, and 60 million doses of another created by France's Valneva. The government in London has also said it would purchase 100 million doses of a vaccine currently being trialed by Oxford University in partnership with AstraZeneca. "This diversity of vaccine types is important because we do not yet know which, if any, of the different types of vaccine will prove to generate a safe and protective response to COVID-19," Kate Bingham, chairwoman of the British government's vaccine taskforce, was quoted as saying. Britain has been one of the worst affected countries in the world since the outbreak began, with more than 45,750 deaths. aue/rl/spm
schema:headline	UK signs up for Sanofi-GSK coronavirus vaccine
schema:mentions	Kingdom of Italy Early access European Commission Nazi Germany University of Oxford AstraZeneca London Pandemic France Pfizer United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 President of the United States Roger Connor Alok Sharma Secretary of State for Business, Energy and Industrial Strategy Aue Sanofi
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-07-29 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	83 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness
http://data.cimple...entionsConspiracy	antivax conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software